Japan recalculates eight drug ingredients due to high sales
It has been decided at a recent meeting of the Chuikyo, the Japanese Central Social Insurance Medical Council, that National Health Insurance drug prices of Japan's best-selling eight ingredients (21 products) which have exceeded the sales forecast before their launches will be to be reduced based on the recalculation method .
The eight ingredients included: Takepron (lansoprazole) and Lansap (lansoprazole/amoxicillin/clarithromycin) from Takeda; Pariet (rabeprazole) and Aricept (donepezil) from Eisai; Omeprazole/Omeprazone(omeprazole) from AstraZeneca/Mitsubishi Pharma; Tamiflu (oseltamivir) from Chugai; Rebetol (ribavirin) from Schering-Plough; and Rituxan (rituximab) from Zenyaku Kogyo.
Products whose sales have reached twice that anticipated before launch and exceed 15.0 billion yen ($127.5 million) are applicable to the recalculation method due to the market expansion. The prices of products can be lowered by an average rate of over 6.7%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze